Stock 600332 GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Shanghai S.E.

Equities

600332

CNE000001733

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
32.08 CNY +0.82% Intraday chart for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited +2.66% +12.17%
Apr. 26 Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 18 Baiyunshan Pharmaceutical's 2023 Profit Rises 2% MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company is in a robust financial situation considering its net cash and margin position.
  • Its low valuation, with P/E ratio at 8.57 and 8.24 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.19 for the 2024 fiscal year.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED Stock Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
+12.17% 6.85B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 681B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 556B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 361B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 325B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.69% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 235B
B+
NOVARTIS AG Stock Novartis AG
+3.65% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 189B
A+
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 874 Stock
  4. 600332 Stock
  5. Ratings Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited